How long should you cycle BPC-157 before taking a break?

Why Cycle at All?

Continuous indefinite dosing of any non-FDA-approved peptide is a weak safety posture. Reasons to use cycles rather than continuous dosing:

• Long-term human safety data are limited. Planned breaks limit cumulative exposure.
• Receptor adaptation concerns. Theoretical, but conservative practice assumes possible downregulation with very long continuous use.
• Forced re-evaluation. Breaks make you ask whether continued use is still justified, rather than defaulting to "keep taking it because it seems to work."
• Cost. BPC-157 adds up over time; breaks are a natural cost control.

Standard Cycle Structures

Acute Injury Protocol

• 6 weeks on
• 2 weeks off
• Optional second cycle of 4–6 weeks if improvement plateaus before full resolution

Chronic Tendinopathy / Difficult Injury Protocol

• 8 weeks on
• 2–4 weeks off
• Second cycle of 6–8 weeks
• 4-week washout and re-evaluation

Gut-Focused Protocol

• 4–8 weeks on
• 2–4 weeks off
• Maintenance cycles (2–3 weeks on, 1–2 weeks off) sometimes used for chronic symptoms under practitioner guidance

Maintenance / Prophylactic Protocol

Some practitioners run shorter periodic maintenance cycles — e.g., 2 weeks on, 2 weeks off — for patients with chronic issues who respond well. This is practitioner-dependent and requires ongoing clinical oversight. It is not the default recommendation.

What to Do During the Off-Cycle

The off-cycle is not wasted time. It is the window for:

• Progressive loading — tendon and ligament remodeling continues after the peptide is stopped. Keep doing the mechanical work.
• Objective reassessment — note any regression in pain, function, or gut symptoms. This tells you whether the on-cycle was producing durable improvement or temporary symptom masking.
• Imaging follow-up — if your provider ordered baseline imaging, the off-cycle is a reasonable window for a re-scan before deciding on another cycle.
• Addressing root causes — if your injury came from training error, ergonomic problems, or biomechanical dysfunction, use the break to work on the underlying driver.

When to Skip the Break and Extend

Rarely appropriate, but sometimes justified:

• Severe post-surgical case approved by surgical team
• Trial of extended 10–12 week cycle under direct medical supervision for slow-responding tendinopathy
• Active IBD adjunct use coordinated with GI specialist

Even in these cases, the default should still be a planned break and reassessment — just shifted to a later point.

When to Stop Completely

• The target issue has fully resolved and been stable for 4+ weeks off the peptide
• No meaningful improvement after 8 weeks of a properly dosed cycle (BPC-157 likely isn't the right tool for your problem)
• Any side effect that doesn't resolve on dose reduction
• Diagnosis of malignancy, until oncology has cleared continued use
• Pregnancy
• Before a competitive athletic event where WADA or sport doping rules apply

Stacking and Cycle Interaction

When BPC-157 is used with TB-500 (Wolverine Stack), both peptides are usually cycled together — 6–8 weeks on, 2–4 weeks off. Don't stagger cycles; running TB-500 continuously while cycling BPC-157 doesn't reflect the usual clinical rationale for either peptide.

See the main BPC-157 guide. Related: dosing for tendonitis, realistic timeline.